↓ Skip to main content

First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases

Overview of attention for article published in Clinical Cancer Research, June 2005
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

policy
1 policy source
twitter
5 tweeters
patent
2 patents
wikipedia
5 Wikipedia pages

Citations

dimensions_citation
359 Dimensions

Readers on

mendeley
165 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases
Published in
Clinical Cancer Research, June 2005
DOI 10.1158/1078-0432.ccr-04-2244
Pubmed ID
Authors

Sten Nilsson, Roy H. Larsen, Sophie D. Fosså, Lise Balteskard, Kari W. Borch, Jan-Erik Westlin, Gro Salberg, Øyvind S. Bruland

Abstract

The main goals were to study the safety and tolerability of the alpha-emitter radium-223 (223Ra) in breast and prostate cancer patients with skeletal metastases. In addition, pain palliation was evaluated.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 165 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 <1%
Italy 1 <1%
Brazil 1 <1%
Spain 1 <1%
United States 1 <1%
Unknown 160 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 28 17%
Other 22 13%
Student > Bachelor 21 13%
Researcher 18 11%
Student > Master 18 11%
Other 33 20%
Unknown 25 15%
Readers by discipline Count As %
Medicine and Dentistry 59 36%
Chemistry 16 10%
Physics and Astronomy 15 9%
Biochemistry, Genetics and Molecular Biology 12 7%
Agricultural and Biological Sciences 8 5%
Other 25 15%
Unknown 30 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 June 2022.
All research outputs
#1,824,493
of 21,745,818 outputs
Outputs from Clinical Cancer Research
#1,447
of 12,334 outputs
Outputs of similar age
#16,386
of 250,252 outputs
Outputs of similar age from Clinical Cancer Research
#10
of 121 outputs
Altmetric has tracked 21,745,818 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,334 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 250,252 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 121 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.